Janssen's IV Simponi wins FDA nod for rheumatoid arthritis

07/19/2013 | Medscape (free registration)

Janssen Biotech obtained the FDA's approval to market an intravenous formulation of Simponi Aria, or golimumab, in combination with methotrexate as a therapy for moderately to severely active rheumatoid arthritis. The drug, a tumor necrosis factor inhibitor, already was cleared for subcutaneous administration. The approval was based on data from a 592-patient, late-stage trial.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT